GlassScriptPhysician profile
Sujankumar K Patel
NPI 1285629790
$2,680.77
in general payments reported to CMS, 2019-2025
26 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $163 · 2021: $584 · 2022: $350 · 2023: $487 · 2024: $261 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,027.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $611.98 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $490.92 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.29 | 2019-2025 | Xifaxan |
| Abbvie INC. | $157.26 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $154.52 | 2020-2024 | Farxiga |
| Alexion Pharmaceuticals, INC. | $133.70 | 2019-2025 | Ultomiris |
| Novo Nordisk INC | $120.13 | 2025 | Ozempic |
| Allergan, INC. | $109.40 | 2019-2020 | |
| Melinta Therapeutics, LLC | $82.85 | 2021-2024 | Rezzayo, Orbactiv, Kimyrsa |
| E.R. Squibb & Sons, L.L.C. | $80.48 | 2019-2022 | |
| Gilead Sciences, INC. | $57.51 | 2021-2022 | |
| Tetraphase Pharmaceuticals, INC. | $38.70 | 2019-2020 | |
| Seagen INC. | $38.04 | 2023 | Padcev, Adcetris |
| Portola Pharmaceuticals, LLC | $37.89 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $36.41 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $35.38 | 2019-2020 | |
| Amgen INC. | $34.47 | 2021-2023 | Repatha |
| Janssen Scientific Affairs, LLC | $30.36 | 2023 | Xarelto |
| Stryker Corporation | $29.57 | 2025 | Flowtriever |
| Pfizer INC. | $27.65 | 2021-2024 | |
| Argenx US, INC. | $27.32 | 2023 | Vyvgart |
| Janssen Biotech, INC. | $20.50 | 2025 | Talvey, Darzalex |
| Daiichi Sankyo INC. | $18.16 | 2024 | Vanflyta |
| Sumitomo Pharma America, INC. | $17.92 | 2025 | Orgovyx |
| Novartis Pharmaceuticals Corporation | $17.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.05 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujankumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.